clinical trials

Galmed files 2025 annual report detailing Aramchol development for NASH and cardiometabolic diseases, including clinical trial progress and regulatory disclosures.

Oculis secures EMA PRIME fast-track designation for Privosegtor, a potential first-in-class neuroprotective optic neuritis therapy, following FDA Breakthrough status in January 2026.

Rosen Law Firm files securities fraud class action against Corcept Therapeutics, alleging misrepresentation of relacorilant drug trial data. Lead plaintiff deadline: April 21, 2026.

Sionna CLO liquidated 10,250 shares for $347k via pre-scheduled plan while retaining 50,935 options. Dual clinical trials expected mid-2026 with $310.3M cash runway through 2028.

Curanex advances Phyto-N toward IND submission in Q4 2026, completing manufacturing and toxicology milestones with secured 12-month funding.

Glucotrack narrowed net losses to $19.4M in 2025 while advancing implantable glucose monitor toward FDA trials in H2 2026.

Rosen Law Firm pursues class action against $CORT for allegedly misrepresenting relacorilant clinical trial data and FDA communications. Lead plaintiff deadline: April 21, 2026.

Viking Therapeutics' VK2735 could threaten Novo Nordisk and Eli Lilly's GLP-1 dominance if phase 3 trials succeed, triggering potential threefold gains or severe losses.

Lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug trials and FDA communications, covering October 2024-December 2025 investor purchases.

Regeneron's 35% recovery masks limited multimillionaire potential at $79B valuation, positioning shares for S&P-matching returns rather than exceptional gains.

Sanofi's isatuximab subcutaneous formulation gains European regulatory endorsement for multiple myeloma, offering patients first cancer treatment with portable injector option.

Autolus Therapeutics reported $74.3M in 2025 AUCATZYL revenue with UK launch underway. Company projects $120-135M in 2026 revenue and positive gross margin expansion.

XORTX Therapeutics shareholders approved all proposals at March 24 meeting with 35% representation, including new leadership and share consolidation.

Apogee Therapeutics CEO sells $1.5M in shares via pre-planned program amid stock's 100% surge, but bullish clinical data and $350M capitalization warrant investor focus.

BullFrog AI ($BFRG) launches bfARENAS, a scenario-based decision engine designed to optimize drug portfolio strategy and clinical trial design for biotech firms.

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

Class action lawsuit filed against $COPT alleging executives misrepresented relacorilant clinical trial strength and FDA approval prospects, harming investors.

Rosen Law Firm notifies Corcept investors about securities lawsuit alleging misrepresentation of relacorilant clinical data and concealment of FDA concerns during October 2024-December 2025.

Class action lawsuit filed against $CORP alleging false statements about relacorilant clinical trial strength and FDA approval prospects. Investors from Oct 2024-Dec 2025 urged to participate.

Kessler Topaz files class action against $QURE over alleged misleading statements about AMT-130 FDA approval timeline, following 49% stock plunge in November 2025.